Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Behav Sci Law ; 38(5): 482-492, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32833256

ABSTRACT

Surveys confirm risk factors for the incarceration of patients with psychosis including homelessness and comorbidity. There is also agreement that severe psychosis can lead to violence. Data describing prisoners with psychosis in Germany are scarce. We aimed to compare patients with psychosis in a prison hospital and patients with psychosis in a community hospital. Demographic data were collected, as well as comorbidity in the form of substance dependence and a psychiatric assessment using the German version of the 18-item Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS). In the prison hospital group more patients were homeless (17 versus 2%) and non-German (36 versus 4%). There were also more patients with substance dependence or abuse in the prison hospital group. The total scores of BPRS and PANSS were lower in the prison hospital group (BPRS, 43.8 versus 51.2; PANSS, 71.5 versus 83.7). We assume that social disintegration for mentally disturbed offenders prior to incarceration hindered effective treatment. To avoid further social disintegration and possible further deterioration of mental health status of released offenders, which may lead to reoffending after imprisonment, discharge management after release from prison should be improved.


Subject(s)
Hospitals, Community , Hospitals, Psychiatric , Inpatients/psychology , Prisoners/psychology , Prisons , Psychotic Disorders/epidemiology , Adult , Brief Psychiatric Rating Scale/statistics & numerical data , Comorbidity , Germany/epidemiology , Ill-Housed Persons/psychology , Humans , Inpatients/statistics & numerical data , Male , Prisoners/statistics & numerical data , Retrospective Studies , Risk Factors , Substance-Related Disorders/epidemiology , Violence/psychology
2.
Anesthesiology ; 99(1): 42-7, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12826840

ABSTRACT

BACKGROUND: Hydroxyethyl starch (HES) 130/0.4 may impair blood coagulation less than other HES solutions and, thus, may be used at larger doses without increasing the risk of postoperative bleeding. This study tested the hypothesis that volume replacement with 6% HES 130/0.4 at a dose of up to 50 ml/kg does not increase blood loss and transfusion requirements in elective coronary artery bypass surgery compared with 6% HES 200/0.5 at a dose of up to 33 ml/kg. METHODS: One hundred twenty adult patients scheduled for elective coronary artery bypass surgery were randomized to receive up to 50 ml/kg of 6% HES 130/0.4 or up to 33 ml/kg of 6% HES 200/0.5 for volume replacement during surgery and until 24 h thereafter. Volume requirements in excess of the respective maximum dose of HES were treated with gelatin. Colloid use was at the discretion of the attending physicians and not dictated by protocol. The primary outcome variable was chest tube drainage volume during the first 24 h after surgery. RESULTS: The data from 117 patients (HES 130/0.4, 59 patients; HES 200/0.5, 58 patients) who completed the study according to protocol were analyzed. The median volumes of HES administered were 49 and 33 ml/kg in the HES 130/0.4 and HES 200/0.5 groups, respectively (P < 0.001). Consequently, patients in the HES 130/0.4 group required less gelatin in addition to HES than those in the HES 200/0.5 group (medians: 7 ml/kg vs. 20 ml/kg, P < 0.001). The combined volumes of HES and gelatin were similar for both groups (P = 0.21). The 24-h chest tube drainage (medians: 660 ml vs. 705 ml, P = 0.60) did not differ significantly between the groups, nor did transfusion outcome. CONCLUSION: Six percent HES 130/0.4 at a median dose of 49 ml/kg did not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with 6% HES 200/0.5 at a median dose of 33 ml/kg.


Subject(s)
Blood Loss, Surgical/physiopathology , Blood Transfusion , Coronary Artery Bypass , Hydroxyethyl Starch Derivatives/administration & dosage , Hydroxyethyl Starch Derivatives/therapeutic use , Plasma Substitutes/administration & dosage , Plasma Substitutes/therapeutic use , Aged , Blood Coagulation Tests , Erythrocyte Transfusion , Female , Humans , Hydroxyethyl Starch Derivatives/adverse effects , Intraoperative Period , Male , Middle Aged , Plasma Substitutes/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL